Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals.
CONCLUSIONS: Significantly higher rates of treatment-adherence and at-target glycemic levels were seen with repaglinide treatment. Weight decreased with acarbose and increased with repaglinide treatment. Hypoglycemic episodes were much less frequent with acarbose treatment.
PMID: 32200914 [PubMed - in process]
Source: The American Journal of the Medical Sciences - Category: General Medicine Authors: Pishdad R, Pishdad P, Pishdad GR Tags: Am J Med Sci Source Type: research
More News: Acarbose | Diabetes | Diabetes Type 2 | Endocrinology | General Medicine | Insulin | Science